Logo

SurroMed, Japanese Genomics Firm to Develop, Sell Biomarkers

Jul 31, 2003

NEW YORK, July 31 - SurroMed and Japanese genomics service company MediBic will co-develop biomarkers for drug discovery, the companies said today.

 

Terms of the deal also call for Tokyo-based MediBic to exclusively sell the biomarkers in Japan.

"We are confident that [MediBic's] ... record and their longstanding relationships will enable us to expand the market in Japan," said SurroMed CEO Gordon Ringold.

SurroMed's biomarker-discovery program pairs sample-preparation techniques with mass spectrometry. SurroMed then uses bioinformatics tools to analyze and mine the data.

MediBic has "relationships" with more than 20 Japanese pharmaceutical and biotechnology companies, according to the company.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.